Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of thre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chongqing, Tan, Sini, Li, Xiaohui, Zeng, Liubao, Peng, Ye, Peng, Shuxia, Qin, Liting, Wang, Meiyu, Wu, Xiaomin, Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712714/
https://www.ncbi.nlm.nih.gov/pubmed/34970153
http://dx.doi.org/10.3389/fphar.2021.802942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712714/
https://www.ncbi.nlm.nih.gov/pubmed/34970153
http://dx.doi.org/10.3389/fphar.2021.802942

Ejemplares similares